Ginger/6-Shogaol/Gingerol / ROS Cancer Research Results

GI, Ginger/6-Shogaol/Gingerol: Click to Expand ⟱
Features:
Flowering plant uses ginger root for help with nausea, weight loss, arthritis, diabetes. Anti-inflammatory and antioxidant.
Gingerol is a phenolic phytochemical compound found in fresh ginger that activates heat receptors on the tongue. It is normally found as a pungent yellow oil in the ginger rhizome.
Ginger contains multiple bioactive compounds including 6-gingerol, 8-gingerol, 10-gingerol, 6-shogaol, paradols, and zingerone.
In cancer-focused literature, the majority of mechanistic work centers on 6-gingerol and 6-shogaol.
Mechanistic themes (preclinical):
-Anti-inflammatory (NF-κB↓, COX-2↓)
-Survival pathway modulation (PI3K/AKT↓, STAT3↓ reported)
-MAPK modulation (ERK/JNK/p38 context-dependent)
-ROS modulation (antioxidant in normal cells; pro-oxidant at higher doses in tumor models)
-Cell-cycle arrest (G1 or G2/M reported)
-Apoptosis induction (mitochondrial pathway)
-Anti-angiogenic and anti-metastatic signaling (VEGF↓, MMPs↓ reported)

Bioavailability note:
-Gingerols are rapidly metabolized (glucuronidation/sulfation)
-Plasma levels after dietary intake are far below many in-vitro micromolar doses
-6-Shogaol is generally more potent than 6-gingerol in cell systems

Ginger / 6-Gingerol / 6-Shogaol — Ginger is the rhizome of Zingiber officinale Roscoe and a botanical mixture containing pungent phenolic compounds, principally 6-gingerol in fresh ginger and increased proportions of 6-shogaol after drying or heating. It is formally classified as a medicinal food and botanical product; 6-gingerol and 6-shogaol are phenolic vanilloids, with 6-shogaol additionally functioning as an electrophilic Michael acceptor. Standard abbreviations include ginger, 6-G, 6-GIN, 6-SG and 6-SHO. Other constituents include 8-gingerol, 10-gingerol, paradols and zingerone. The anticancer evidence is predominantly preclinical and should not be equated with the established clinical use of ginger for nausea.

Primary mechanisms (ranked):

  1. Electrophilic protein modification by 6-shogaol, including HSP60 destabilization and modulation of KEAP1 and other cysteine-sensitive proteins.
  2. Suppression of NF-κB, COX-2, iNOS and inflammatory cytokine signaling.
  3. Suppression of PI3K/AKT/mTOR and STAT3 survival signaling.
  4. Mitochondrial dysfunction, oxidative stress and intrinsic caspase-dependent apoptosis in cancer cells.
  5. Cell-cycle arrest through model-dependent modulation of cyclins, CDKs and checkpoint proteins.
  6. Suppression of EMT, MMP activity, migration, invasion and angiogenic signaling.
  7. NRF2-mediated cytoprotective and antioxidant signaling, particularly in normal or inflammatory tissue; this is context-dependent and may oppose oxidative cytotoxicity in some cancer settings.
  8. Potential chemosensitization through disruption of survival signaling and stress-response proteins; evidence remains preclinical.

Bioavailability / PK relevance: Gingerols and shogaols are absorbed orally but undergo extensive first-pass glucuronidation and sulfation. Circulating exposure consists predominantly of conjugated metabolites rather than free parent compounds. 6-Shogaol is generally more reactive and more potent than 6-gingerol in cell models, but it is chemically and metabolically unstable. Glucuronidation markedly reduces its cytotoxic and NRF2-modulating activity. Botanical preparations vary substantially according to cultivar, extraction method, storage, drying and heating.

In-vitro vs systemic exposure relevance: Most anticancer experiments use approximately 10–100 µM parent 6-gingerol or 6-shogaol. These concentrations generally exceed sustained free systemic exposure achievable through ordinary dietary ginger or conventional oral supplements. Colon and gastrointestinal tissues may receive greater local exposure to parent compounds and metabolites than distant tumors. The observed selectivity between malignant and normal cells remains model-dependent rather than clinically established.

Clinical evidence status: Anticancer treatment evidence remains preclinical, consisting mainly of cell studies and animal xenograft models. Small randomized human studies have examined colorectal mucosal biomarkers, inflammatory eicosanoids and chemotherapy-induced nausea rather than tumor regression or survival. Results for chemotherapy-induced nausea are mixed, although some trials report improved quality of life or reduced acute symptoms when ginger is used adjunctively with standard antiemetics. Ginger is not an approved anticancer therapy, and purified 6-gingerol or 6-shogaol has not demonstrated clinical anticancer efficacy.

Safety / interaction constraints: Food-level ginger is generally well tolerated; concentrated supplements can cause gastrointestinal discomfort or heartburn. Platelet inhibition and clinically relevant bleeding interactions remain incompletely defined, but caution is appropriate with warfarin, direct oral anticoagulants, antiplatelet drugs, bleeding disorders and surgery. Product standardization is important because dried or thermally processed ginger may contain substantially more 6-shogaol than fresh ginger.

Gingerol and Shogaol Mechanistic Profile

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Electrophilic protein targeting and HSP60 stability HSP60 stability ↓; proteasomal degradation ↑; mitochondrial function ↓ Electrophile-responsive proteins modulated (context-dependent) P, R Proteotoxic and mitochondrial stress Most directly demonstrated for 6-shogaol. Its α,β-unsaturated carbonyl can react with protein cysteines; this mechanism should not automatically be assigned to non-electrophilic ginger constituents.
2 NF-κB inflammatory transcription IKK activity ↓; NF-κB activation ↓; COX-2 ↓; iNOS ↓; TNF-α and IL-6 ↓ Inflammatory signaling ↓; endothelial activation ↓ R, G Anti-inflammatory and anti-survival signaling A recurring effect of ginger extracts, gingerols and 6-shogaol, although potency and direct molecular targets differ among preparations.
3 PI3K AKT mTOR survival axis PI3K ↓; AKT phosphorylation ↓; mTOR signaling ↓ AKT may be preserved or ↑ during tissue protection (context-dependent) R, G Growth suppression and apoptosis sensitization Direction differs by biological context. Suppression is reported in cancer models, whereas activation can contribute to protection from ischemic or inflammatory injury.
4 STAT3 survival transcription STAT3 phosphorylation ↓; nuclear signaling ↓; survival proteins ↓ ↔ (model-dependent) R, G Proliferation and survival suppression 6-Shogaol has inhibited constitutive and inducible STAT3 signaling in several tumor models.
5 Mitochondrial apoptosis Mitochondrial membrane potential ↓; Bax/Bcl-2 ratio ↑; cytochrome c release ↑; caspase-9 and caspase-3 ↑; PARP cleavage ↑ Apoptosis ↓ during some injury models (context-dependent) R, G Intrinsic apoptosis Often downstream of HSP60 destabilization, oxidative stress and AKT or STAT3 suppression.
6 ROS and redox stress ROS ↑ at cytotoxic concentrations; oxidative damage ↑; apoptosis ↑ (dose-dependent) ROS ↓; antioxidant defenses ↑ P, R Biphasic redox modulation Pro-oxidant cancer effects generally occur at micromolar concentrations. Antioxidant and cytoprotective effects predominate in many normal-cell and inflammatory models.
7 KEAP1 NRF2 antioxidant response NRF2 ↑ (context-dependent); possible cytoprotection or treatment resistance NRF2 ↑; HO-1 ↑; NQO1 ↑; glutathione-related enzymes ↑ R, G Secondary cytoprotective response 6-Shogaol can modify cysteine-sensitive NRF2 regulatory mechanisms. NRF2 activation is protective in normal tissue but may be undesirable in NRF2-dependent tumors.
8 MAPK stress signaling JNK and p38 modulation; ERK ↓ or transiently ↑ (context-dependent) Stress-MAPK activation ↓ or adaptive signaling ↑ (context-dependent) P, R Stress signaling and inflammatory regulation MAPK direction varies by compound, dose, cell type and sampling time; it should not be represented as uniformly activated or inhibited.
9 Cell-cycle checkpoints G1 or G2/M arrest ↑; cyclin D1 ↓; cyclin B1 and CDK modulation G Cytostasis The arrested phase is tumor-model dependent and may differ between 6-gingerol, 6-shogaol and whole-ginger extracts.
10 EMT migration and matrix degradation Snail ↓; N-cadherin ↓; MMP-2 and MMP-9 ↓; migration and invasion ↓ Endothelial and leukocyte migration ↓ during inflammation G Anti-invasive phenotype Frequently linked to inhibition of IKK, NF-κB, STAT3 and AKT signaling.
11 Angiogenic signaling VEGF expression ↓; endothelial recruitment and tube formation ↓ Inflammation-associated angiogenesis ↓ G Anti-angiogenic activity Evidence is preclinical and includes direct endothelial effects; impaired physiological angiogenesis is a theoretical context-dependent concern.
12 Chemosensitization Taxane, platinum or other drug response ↑ (model-dependent) Normal-tissue toxicity may ↓ in selected models (model-dependent) G Adjunctive treatment sensitization Reported mechanisms include HSP60 destabilization and suppression of AKT, mTOR, STAT3 and NF-κB. No clinical sensitization benefit has been established.
13 Clinical Translation Constraint Free parent exposure low; rapid conjugation; botanical composition heterogeneous Bleeding interaction and gastrointestinal tolerability require consideration Exposure and evidence limitation Most cytotoxic experiments use free parent concentrations substantially above sustained human plasma exposure. Existing human trials primarily address nausea or biomarkers rather than cancer treatment efficacy.

P: 0–30 min    R: 30 min–3 hr    G: >3 hr



ROS, Reactive Oxygen Species: Click to Expand ⟱
Source: HalifaxProj (inhibit)
Type:
Reactive oxygen species (ROS) are highly reactive molecules that contain oxygen and can lead to oxidative stress in cells. They play a dual role in cancer biology, acting as both promoters and suppressors of cancer.
ROS can cause oxidative damage to DNA, leading to mutations that may contribute to cancer initiation and progression. So normally you want to inhibit ROS to prevent cell mutations.
However excessive ROS can induce apoptosis (programmed cell death) in cancer cells, potentially limiting tumor growth. Chemotherapy typically raises ROS.
-mitochondria is the main source of reactive oxygen species (ROS) (and the ETC is heavily related)
ROS Homeostasis in Cancer Cells and Its Potential as a Therapeutic Target

"Reactive oxygen species (ROS) are two electron reduction products of oxygen, including superoxide anion, hydrogen peroxide, hydroxyl radical, lipid peroxides, protein peroxides and peroxides formed in nucleic acids 1. They are maintained in a dynamic balance by a series of reduction-oxidation (redox) reactions in biological systems and act as signaling molecules to drive cellular regulatory pathways."
"During different stages of cancer formation, abnormal ROS levels play paradoxical roles in cell growth and death 8. A physiological concentration of ROS that maintained in equilibrium is necessary for normal cell survival. Ectopic ROS accumulation promotes cell proliferation and consequently induces malignant transformation of normal cells by initiating pathological conversion of physiological signaling networks. Excessive ROS levels lead to cell death by damaging cellular components, including proteins, lipid bilayers, and chromosomes. Therefore, both scavenging abnormally elevated ROS to prevent early neoplasia and facilitating ROS production to specifically kill cancer cells are promising anticancer therapeutic strategies, in spite of their contradictoriness and complexity."
"ROS are the collection of derivatives of molecular oxygen that occur in biology, which can be categorized into two types, free radicals and non-radical species. The non-radical species are hydrogen peroxide (H 2O 2 ), organic hydroperoxides (ROOH), singlet molecular oxygen ( 1 O 2 ), electronically excited carbonyl, ozone (O3 ), hypochlorous acid (HOCl, and hypobromous acid HOBr). Free radical species are super-oxide anion radical (O 2•−), hydroxyl radical (•OH), peroxyl radical (ROO•) and alkoxyl radical (RO•) [130]. Any imbalance of ROS can lead to adverse effects. H2 O 2 and O 2 •− are the main redox signalling agents. The cellular concentration of H2 O 2 is about 10−8 M, which is almost a thousand times more than that of O2 •−".
"Radicals are molecules with an odd number of electrons in the outer shell [393,394]. A pair of radicals can be formed by breaking a chemical bond or electron transfer between two molecules."

Recent investigations have documented that polyphenols with good antioxidant activity may exhibit pro-oxidant activity in the presence of copper ions, which can induce apoptosis in various cancer cell lines but not in normal cells. "We have shown that such cell growth inhibition by polyphenols in cancer cells is reversed by copper-specific sequestering agent neocuproine to a significant extent whereas iron and zinc chelators are relatively ineffective, thus confirming the role of endogenous copper in the cytotoxic action of polyphenols against cancer cells. Therefore, this mechanism of mobilization of endogenous copper." > Ions could be one of the important mechanisms for the cytotoxic action of plant polyphenols against cancer cells and is possibly a common mechanism for all plant polyphenols. In fact, similar results obtained with four different polyphenolic compounds in this study, namely apigenin, luteolin, EGCG, and resveratrol, strengthen this idea.
Interestingly, the normal breast epithelial MCF10A cells have earlier been shown to possess no detectable copper as opposed to breast cancer cells [24], which may explain their resistance to polyphenols apigenin- and luteolin-induced growth inhibition as observed here (Fig. 1). We have earlier proposed [25] that this preferential cytotoxicity of plant polyphenols toward cancer cells is explained by the observation made several years earlier, which showed that copper levels in cancer cells are significantly elevated in various malignancies. Thus, because of higher intracellular copper levels in cancer cells, it may be predicted that the cytotoxic concentrations of polyphenols required would be lower in these cells as compared to normal cells."

Majority of ROS are produced as a by-product of oxidative phosphorylation, high levels of ROS are detected in almost all cancers.
-It is well established that during ER stress, cytosolic calcium released from the ER is taken up by the mitochondrion to stimulate ROS overgeneration and the release of cytochrome c, both of which lead to apoptosis.

Note: Products that may raise ROS can be found using this database, by:
Filtering on the target of ROS, and selecting the Effect Direction of ↑

Targets to raise ROS (to kill cancer cells):
• NADPH oxidases (NOX): NOX enzymes are involved in the production of ROS.
    -Targeting NOX enzymes can increase ROS levels and induce cancer cell death.
    -eNOX2 inhibition leads to a high NADH/NAD⁺ ratio which can lead to increased ROS
• Mitochondrial complex I: Inhibiting can increase ROS production
• P53: Activating p53 can increase ROS levels(by inducing the expression of pro-oxidant genes)
Nrf2 inhibition: regulates the expression of antioxidant genes. Inhibiting Nrf2 can increase ROS levels
• Glutathione (GSH): an antioxidant. Depleting GSH can increase ROS levels
• Catalase: Catalase converts H2O2 into H2O+O. Inhibiting catalase can increase ROS levels
• SOD1: converts superoxide into hydrogen peroxide. Inhibiting SOD1 can increase ROS levels
• PI3K/AKT pathway: regulates cell survival and metabolism. Inhibiting can increase ROS levels
HIF-1α inhibition: regulates genes involved in metabolism and angiogenesis. Inhibiting HIF-1α can increase ROS
• Glycolysis: Inhibiting glycolysis can increase ROS levels • Fatty acid oxidation: Cancer cells often rely on fatty acid oxidation for energy production.
-Inhibiting fatty acid oxidation can increase ROS levels
• ER stress: Endoplasmic reticulum (ER) stress can increase ROS levels
• Autophagy: process by which cells recycle damaged organelles and proteins.
-Inhibiting autophagy can increase ROS levels and induce cancer cell death.
• KEAP1/Nrf2 pathway: regulates the expression of antioxidant genes.
    -Inhibiting KEAP1 or activating Nrf2 can increase ROS levels and induce cancer cell death.
• DJ-1: regulates the expression of antioxidant genes. Inhibiting DJ-1 can increase ROS levels
• PARK2: regulates the expression of antioxidant genes. Inhibiting PARK2 can increase ROS levels
SIRT1 inhibition:regulates the expression of antioxidant genes. Inhibiting SIRT1 can increase ROS levels
AMPK activation: regulates energy metabolism and can increase ROS levels when activated.
mTOR inhibition: regulates cell growth and metabolism. Inhibiting mTOR can increase ROS levels
HSP90 inhibition: regulates protein folding and can increase ROS levels when inhibited.
• Proteasome: degrades damaged proteins. Inhibiting the proteasome can increase ROS levels
Lipid peroxidation: a process by which lipids are oxidized, leading to the production of ROS.
    -Increasing lipid peroxidation can increase ROS levels
• Ferroptosis: form of cell death that is regulated by iron and lipid peroxidation.
    -Increasing ferroptosis can increase ROS levels
• Mitochondrial permeability transition pore (mPTP): regulates mitochondrial permeability.
    -Opening the mPTP can increase ROS levels
• BCL-2 family proteins: regulate apoptosis and can increase ROS levels when inhibited.
• Caspase-independent cell death: a form of cell death that is regulated by ROS.
    -Increasing caspase-independent cell death can increase ROS levels
• DNA damage response: regulates the repair of DNA damage. Increasing DNA damage can increase ROS
• Epigenetic regulation: process by which gene expression is regulated.
    -Increasing epigenetic regulation can increase ROS levels

-PKM2, but not PKM1, can be inhibited by direct oxidation of cysteine 358 as an adaptive response to increased intracellular reactive oxygen species (ROS)

ProOxidant Strategy:(inhibit the Mevalonate Pathway (likely will also inhibit GPx)
-HydroxyCitrate (HCA) found as supplement online and typically used in a dose of about 1.5g/day or more
-Atorvastatin typically 40-80mg/day, -Dipyridamole typically 200mg 2x/day Combined effect research
-Lycopene typically 100mg/day range (note debatable as it mainly lowers NRF2)

Dual Role of Reactive Oxygen Species and their Application in Cancer Therapy
ROS-Inducing Interventions in Cancer — Canonical + Mechanistic Reference
-generated from AI and Cancer database
ROS rating:  +++ strong | ++ moderate | + weak | ± mixed | 0 none
NRF2:        ↓ suppressed | ↑ activated | ± mixed | 0 none
Conditions:  [D] dose  [Fe] metal  [M] metabolic  [O₂] oxygen
             [L] light [F] formulation [T] tumor-type [C] combination

Item ROS NRF2 Condition Mechanism Class Remarks
ROS">Piperlongumine +++ [D][T] ROS-dominant
ROS">Shikonin +++↓/±[D][T]ROS-dominant
ROS">Vitamin K3 (menadione) +++[D]ROS-dominant
ROS">Copper (ionic / nano) +++[Fe][F]ROS-dominant
ROS">Sodium Selenite +++[D]ROS-dominant
ROS">Juglone +++[D]ROS-dominant
ROS">Auranofin +++[D]ROS-dominant
ROS">Photodynamic Therapy (PDT) +++0[L][O₂]ROS-dominant
ROS">Radiotherapy / Radiation +++0[O₂]ROS-dominant
ROS">Doxorubicin +++[D]ROS-dominant
ROS">Cisplatin ++[D][T]ROS-dominant
ROS">Salinomycin ++[D][T]ROS-dominant
ROS">Artemisinin / DHA ++[Fe][T]ROS-dominant
ROS">Sulfasalazine ++[C][T]ROS-dominant
ROS">FMD / fasting ++[M][C][O₂]ROS-dominant
ROS">Vitamin C (pharmacologic) ++[Fe][D]ROS-dominant
ROS">Silver nanoparticles ++±[F][D]ROS-dominant
ROS">Gambogic acid ++[D][T]ROS-dominant
ROS">Parthenolide ++[D][T]ROS-dominant
ROS">Plumbagin ++[D]ROS-dominant
ROS">Allicin ++[D]ROS-dominant
ROS">Ashwagandha (Withaferin A) ++[D][T]ROS-dominant
ROS">Berberine ++[D][M]ROS-dominant
ROS">PEITC ++[D][C]ROS-dominant
ROS">Methionine restriction +[M][C][T]ROS-secondary
ROS">DCA +±[M][T]ROS-secondary
ROS">Capsaicin +±[D][T]ROS-secondary
ROS">Galloflavin +0[D]ROS-secondary
ROS">Piperine +±[D][F]ROS-secondary
ROS">Propyl gallate +[D]ROS-secondary
ROS">Scoulerine +?[D][T]ROS-secondary
ROS">Thymoquinone ±±[D][T]Dual redox
ROS">Emodin ±±[D][T]Dual redox
ROS">Alpha-lipoic acid (ALA) ±[D][M]NRF2-dominant
ROS">Curcumin ±↑/↓[D][F]NRF2-dominant
ROS">EGCG ±↑/↓[D][O₂]NRF2-dominant
ROS">Quercetin ±↑/↓[D][Fe]NRF2-dominant
ROS">Resveratrol ±[D][M]NRF2-dominant
ROS">Sulforaphane ±↑↑[D]NRF2-dominant
ROS">Lycopene 0Antioxidant
ROS">Rosmarinic acid 0Antioxidant
ROS">Citrate 00Neutral


Scientific Papers found: Click to Expand⟱
7140- GI,    Benefits of Ginger and Its Constituent 6-Shogaol in Inhibiting Inflammatory Processes
- Review, Var, NA
*Dose↝, *Inflam↓, *COX2↓, *iNOS↓, *NF-kB↓, *MAPK?, *HO-1↑, *PGE2↓, *TNF-α↓, *IL6↓, *IL1β↓, *IFN-γ↓, *MCP1/CCL2↓, *MIP2↓, *RANTES↓, *MPO↓, *NO↓, *Stroke↓, *BrainVol↑, *MDA↓, *ROS↓, *GSH↑, *NRF2↑, *antiOx↑, NLRP3↓, HDAC1↓,
7156- GI,    Ginger-derived nanoparticles protect against alcohol-induced liver damage
- in-vivo, Nor, NA
*hepatoP↑, *NRF2↑, *ROS↑,
7138- GI,    6-Shogaol exerts anti-proliferative and pro-apoptotic effects through the modulation of STAT3 and MAPKs signaling pathways
- vitro+vivo, BC, MDA-MB-231 - in-vitro, Pca, DU145 - in-vitro, Liver, HepG2 - in-vitro, Lung, A549
TumCP↓, TumMeta↓, p‑STAT3↓, JAK2↓, cSrc↓, JNK↑, p38↑, ERK↑, eff↓, ROS↑, cl‑PARP↑, TumCCA↑, Casp8↑, Casp9↑, Casp3↑, eff↑, Bcl-2↑, Bcl-xL↓, survivin↓, MMP9↓, COX2↓, IAP1↓, Dose?,

Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1)

ROS↑, 1,  

Cell Death(tgid=5)

Bcl-2↑, 1,   Bcl-xL↓, 1,   Casp3↑, 1,   Casp8↑, 1,   Casp9↑, 1,   IAP1↓, 1,   JNK↑, 1,   p38↑, 1,   survivin↓, 1,  

Kinase & Signal Transduction(tgid=6)

cSrc↓, 1,  

DNA Damage & Repair(tgid=10)

cl‑PARP↑, 1,  

Cell Cycle & Senescence(tgid=11)

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12)

ERK↑, 1,   HDAC1↓, 1,   p‑STAT3↓, 1,  

Migration(tgid=13)

MMP9↓, 1,   TumCP↓, 1,   TumMeta↓, 1,  

Immune & Inflammatory Signaling(tgid=16)

COX2↓, 1,   JAK2↓, 1,  

Protein Aggregation(tgid=19)

NLRP3↓, 1,  

Drug Metabolism & Resistance(tgid=21)

Dose?, 1,   eff↓, 1,   eff↑, 1,  
Total Targets: 25

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0)

Stroke↓, 1,  

Redox & Oxidative Stress(tgid=1)

antiOx↑, 1,   GSH↑, 1,   HO-1↑, 1,   MDA↓, 1,   MPO↓, 1,   NRF2↑, 2,   ROS↓, 1,   ROS↑, 1,  

Cell Death(tgid=5)

iNOS↓, 1,   MAPK?, 1,  

Angiogenesis & Vasculature(tgid=14)

NO↓, 1,  

Immune & Inflammatory Signaling(tgid=16)

COX2↓, 1,   IFN-γ↓, 1,   IL1β↓, 1,   IL6↓, 1,   Inflam↓, 1,   MCP1/CCL2↓, 1,   MIP2↓, 1,   NF-kB↓, 1,   PGE2↓, 1,   RANTES↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission(tgid=18)

BrainVol↑, 1,  

Drug Metabolism & Resistance(tgid=21)

Dose↝, 1,  

Clinical Biomarkers(tgid=22)

IL6↓, 1,  

Functional Outcomes(tgid=23)

hepatoP↑, 1,  
Total Targets: 27

Scientific Paper Hit Count for: ROS, Reactive Oxygen Species
3 Ginger/6-Shogaol/Gingerol
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:88  Target#:275  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page